Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

Egyptian Liver Journal

Table 8 Classifying Child B cases into low- and high-risk groups for TACE according to the AFP model

		Child B		Test value	P value	Sig.
		Low-risk	High-risk
		No. = 5	No. = 8
Response	Complete response	4 (80.0%)	6 (75.0%)	0.043*	0.835	NS
	Partial response	1 (20.0%)	2 (25.0%)
	Stationary disease	0 (0.0%)	0 (0.0%)
	Progressive disease	0 (0.0%)	0 (0.0%)
Recurrence	No recurrence	0 (0.0%)	1 (16.7%)	0.741*	0.389	NS
Recurrence	Recurrence	4 (100.0%)	5 (83.3%)	0.741*	0.389	NS
Recurrence-free survival	Median (IQR)	12 (6–17)	4.5 (3–15)	− 0.829≠	0.407	NS
Recurrence-free survival	Range	3–24	3–29	− 0.829≠	0.407	NS
OS (months)	Median (IQR)	18 (15–22)	12.5 (9–25.5)	− 0.882≠	0.378	NS
OS (months)	Range	13–24	8–32	− 0.882≠	0.378	NS